Literature DB >> 30655367

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.

Barbara Muz1, Maurizio Buggio2, Feda Azab1, Pilar de la Puente1, Mark Fiala3, Mahesh V Padval4, David T Weaver4, Jonathan A Pachter4, Ravi Vij3, Abdel Kareem Azab5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30655367      PMCID： PMC6601110          DOI： 10.3324/haematol.2018.194688

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Authors:  Barbara Muz; Hubert D Kusdono; Feda Azab; Pilar de la Puente; Cinzia Federico; Mark Fiala; Ravi Vij; Noha N Salama; Abdel Kareem Azab
Journal:  Leuk Lymphoma       Date:  2017-05-16

2.  Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Authors:  Abdel Kareem Azab; Jinsong Hu; Phong Quang; Feda Azab; Costas Pitsillides; Rana Awwad; Brian Thompson; Patricia Maiso; Jessica D Sun; Charles P Hart; Aldo M Roccaro; Antonio Sacco; Hai T Ngo; Charles P Lin; Andrew L Kung; Ruben D Carrasco; Karin Vanderkerken; Irene M Ghobrial
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

3.  Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

Authors:  Paola Neri; Li Ren; Abdel Kareem Azab; Matthew Brentnall; Kathy Gratton; Alexander C Klimowicz; Charles Lin; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Lawrence H Boise; Irene M Ghobrial; Nizar J Bahlis
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

4.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

5.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Authors:  Abdel Kareem Azab; Feda Azab; Simona Blotta; Costas M Pitsillides; Brian Thompson; Judith M Runnels; Aldo M Roccaro; Hai T Ngo; Molly R Melhem; Antonio Sacco; Xiaoying Jia; Kenneth C Anderson; Charles P Lin; Barrett J Rollins; Irene M Ghobrial
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

6.  3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Barbara Muz; Rebecca C Gilson; Feda Azab; Micah Luderer; Justin King; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  Biomaterials       Date:  2015-09-12       Impact factor: 12.479

7.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Authors:  Abdel Kareem Azab; Judith M Runnels; Costas Pitsillides; Anne-Sophie Moreau; Feda Azab; Xavier Leleu; Xiaoying Jia; Renee Wright; Beatriz Ospina; Alicia L Carlson; Clemens Alt; Nicholas Burwick; Aldo M Roccaro; Hai T Ngo; Mena Farag; Molly R Melhem; Antonio Sacco; Nikhil C Munshi; Teru Hideshima; Barrett J Rollins; Kenneth C Anderson; Andrew L Kung; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

8.  Pyk2 promotes tumor progression in multiple myeloma.

Authors:  Yu Zhang; Michele Moschetta; Daisy Huynh; Yu-Tzu Tai; Yong Zhang; Wenjing Zhang; Yuji Mishima; Jennifer E Ring; Winnie F Tam; Qunli Xu; Patricia Maiso; Michaela Reagan; Ilyas Sahin; Antonio Sacco; Salomon Manier; Yosra Aljawai; Siobhan Glavey; Nikhil C Munshi; Kenneth C Anderson; Jonathan Pachter; Aldo M Roccaro; Irene M Ghobrial
Journal:  Blood       Date:  2014-09-12       Impact factor: 22.113

9.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

10.  Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.

Authors:  Barbara Muz; Feda Azab; Pilar de la Puente; Scott Rollins; Richard Alvarez; Ziad Kawar; Abdel Kareem Azab
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411
View more
  7 in total

1.  Systematic Identification of Genomic Markers for Guiding Iron Oxide Nanoparticles in Cervical Cancer Based on Translational Bioinformatics.

Authors:  Haohan Zhou; Jiayi Tian; Hongyu Sun; Jiaying Fu; Nan Lin; Danni Yuan; Li Zhou; Meihui Xia; Liankun Sun
Journal:  Int J Nanomedicine       Date:  2022-06-29

2.  Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.

Authors:  Cinzia Federico; Jennifer Sun; Barbara Muz; Kinan Alhallak; Pippa F Cosper; Naoshad Muhammad; Amanda Jeske; Amanda Hinger; Stephanie Markovina; Perry Grigsby; Julie K Schwarz; Abdel Kareem Azab
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-27       Impact factor: 7.038

Review 3.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.

Authors:  Yinyin Xu; Jing Guo; Jing Liu; Ying Xie; Xin Li; Hongmei Jiang; Jingjing Wang; Ziyi Peng; Jingya Wang; Sheng Wang; Chao Wan; Lanting Chen; Yuping Zhong; Beizhong Liu; Zhiqiang Liu
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

Review 5.  Focal adhesion kinase inhibitors, a heavy punch to cancer.

Authors:  Yueling Wu; Ning Li; Chengfeng Ye; Xingmei Jiang; Hui Luo; Baoyuan Zhang; Ying Zhang; Qingyu Zhang
Journal:  Discov Oncol       Date:  2021-11-22

6.  A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.

Authors:  Kinan Alhallak; Amanda Jeske; Pilar de la Puente; Jennifer Sun; Mark Fiala; Feda Azab; Barbara Muz; Ilyas Sahin; Ravi Vij; John F DiPersio; Abdel Kareem Azab
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

7.  Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide in vitro and in vivo.

Authors:  Jianrong Yang; Jingtao Zhong; Mi Zhou; Yinghong Zhou; Peng Xiu; Feng Liu; Fuhai Wang; Zelun Li; Yuntian Tang; Yuanyuan Chen; Siyang Yao; Tao Huang; Tianqi Liu; Xiaofeng Dong
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.